FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.
| Website | https://www.forxtx.com |
| Revenue | $81.8 million |
| Employees | 34 (17 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research |
| Competitors | AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences, Regeneron, Vertex Pharmaceuticals, Pfizer, Johnson & Johnson, Merck & Co., Inc., Novartis +48 more (view full list) |
Looking for a particular FoRx Therapeutics employee's phone or email?
FoRx Therapeutics Questions
The FoRx Therapeutics annual revenue was $81.8 million in 2026.
Frank Zenke is the Chief Scientific Officer of FoRx Therapeutics.
17 people are employed at FoRx Therapeutics.
Top FoRx Therapeutics Employees
-
2
-
Irena Konstantinova
Head of Biology at FoRx Therapeutics
Basel, BS, CH1 -
Olivier Querolle
Senior Director Medicinal Chemistry at FoRx Therapeutics
Saint-Louis, Grand Est, FR2 -
2
-
Jason Clochard
Research associate at FoRx Therapeutics
Basel, BS, CH1 -
Sambhav Sharma
Network Marketer at FoRx Therapeutics
Dehradun, UK, IN
